Synopsys Launches $1 Billion Accelerated Share Repurchase With JPMorgan

Synopsys has entered into a $1 billion accelerated share repurchase agreement with JPMorgan Chase Bank, N.A., turning a capital-return plan outlined at its recent Investor Day into an immediate buyback. The semiconductor design software company said it expects to receive an initial delivery of about 1.735 million shares, with the final number of shares determined later under the agreement’s pricing formula.

The arrangement gives Synopsys a large portion of the economic effect of the buyback up front rather than requiring the company to purchase shares gradually in the open market. JPMorgan will deliver the initial shares now, while the ultimate number Synopsys retires will depend on the average of its daily volume-weighted average share prices during the repurchase period, less a discount. Any remaining settlement is due on or before January 5, 2027.

Synopsys disclosed the terms in its October 5 announcement. The company did not specify a fixed final share count because the ASR structure makes that number dependent on Synopsys’s share price during the repurchase period. The initial delivery therefore should not be read as the final number of shares that will ultimately be repurchased.

The buyback follows Synopsys’s Investor Day capital-return plan

The timing is notable because Synopsys had signaled the move only days earlier. At its September 30 Investor Day, management said it intended to repurchase approximately $1 billion of shares over the coming months, subject to market conditions. It also laid out a broader capital-allocation framework under which the company expects to return up to 50% of free cash flow to shareholders through share repurchases after funding investment in the business.

The ASR effectively accelerates that stated plan. Instead of waiting for a series of open-market purchases, Synopsys is using JPMorgan to execute a large repurchase under a structure that provides an immediate initial share delivery and then settles based on average trading prices over a defined period. That can give a company faster reduction in its outstanding share count while leaving the final number of repurchased shares dependent on the stock’s performance during the program.

Synopsys had already expanded its repurchase capacity earlier in the fiscal year. In February, its board replenished the existing stock repurchase program with authorization to buy up to $2 billion of common stock. In March, the company entered into a separate $250 million accelerated share repurchase with The Bank of Nova Scotia, under which it initially received about 513,000 shares. Synopsys has not said in the latest announcement how much authorization will remain after the new $1 billion program is completed, so the current story is best framed around the newly announced ASR rather than an inferred remaining balance.

How the accelerated repurchase works

An accelerated share repurchase differs from a standard open-market buyback mainly in timing and execution. Synopsys is paying for the $1 billion program through the agreement with JPMorgan and receiving a large initial block of shares at the outset. JPMorgan then manages the market purchases needed to support the arrangement over the repurchase period. Once that period ends, the parties calculate the final number of shares based on the agreed pricing formula.

For Synopsys shareholders, the most important number at this stage is the $1 billion commitment, not the initial 1.735 million-share delivery in isolation. The final share count could be higher or lower depending on the average daily VWAP during the period, after applying the contractual discount. Synopsys also noted that settlement could occur before the January 5 deadline if the repurchase process is completed earlier.

Share repurchases can reduce the number of shares outstanding, which can increase per-share measures such as earnings per share if other factors remain unchanged. They also return capital to shareholders indirectly by using corporate cash to acquire and retire equity. The actual economic effect depends on the prices paid, the company’s future earnings and cash generation, and whether management could have earned a better return by deploying the capital elsewhere. Synopsys has presented the current repurchase as part of a framework that seeks to balance internal investment with capital returns rather than as a substitute for growth spending.

The company’s balance sheet and cash generation provide useful context for that choice. At the end of its fiscal third quarter on July 31, Synopsys reported about $3.61 billion of cash, cash equivalents and short-term investments. It also raised its fiscal 2026 free-cash-flow target to about $2.6 billion in August. Those figures do not by themselves determine how the buyback will be funded or what future repurchases will look like, but they show why management has room to discuss larger capital returns alongside continued investment in the business.

Capital returns are becoming a larger part of the Synopsys story

The $1 billion ASR comes as Synopsys is trying to convince investors that stronger cash generation can coexist with continued spending on engineering software, silicon intellectual property and the expanded portfolio that followed its acquisition of Ansys. At Investor Day, management projected roughly 15% fiscal 2027 revenue growth at the midpoint of guidance and outlined a longer-term goal of mid-teens revenue growth through fiscal 2030, along with expanding non-GAAP operating margins and free cash flow.

Those targets are forward-looking and depend on execution, but they help explain why the company paired its growth presentation with a more explicit shareholder-return policy. A commitment to return up to half of free cash flow through repurchases creates a clearer framework for excess cash after business investment, while the accelerated buyback demonstrates that management is willing to use that capacity in sizable blocks.

The latest ASR is also much larger than the $250 million accelerated repurchase Synopsys announced in March. That earlier agreement provided an initial delivery of roughly 513,000 shares and was scheduled to settle by June 1. The new JPMorgan agreement quadruples the dollar commitment and shortens the gap between Synopsys’s public capital-return guidance and actual execution.

The next concrete milestone is final settlement. Synopsys expects the ASR to be completed no later than January 5, 2027, at which point the company will know the final number of shares repurchased under the $1 billion agreement. Until then, the initial 1.735 million-share delivery provides an early reduction in the share count, while the final outcome remains tied to Synopsys’s average trading price during the repurchase period.